YAP inhibition overcomes adaptive resistance in HER2-positive gastric cancer treated with trastuzumab via the AKT/mTOR and ERK/mTOR axis
Gastric Cancer · 2024
DOI: 10.1007/s10120-024-01508-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Gastric Cancer, 2024. Verfasst von Jiao Qiao und 9 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Medical Technology, Peking University Health Science Center, Beijing, 100191, China. Hauptthemen laut MEDLINE: Stomach Neoplasms, Trastuzumab, Erb-b2 Receptor Tyrosine Kinases, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Beijing Clinical Key Specialty Excellence Program, P. R. China, Hospital-Enterprise Joint Funding Project.
Abstract (Originalsprache)
Background
Human epidermal growth factor receptor 2 (HER2)-positive gastric cancer (GC) is a heterogeneous GC subtype characterized by the overexpression of HER2. To date, few specific targeted therapies have demonstrated durable efficacy in HER2-positive GC patients, with resistance to trastuzumab typically emerging within 1 year. However, the mechanisms of resistance to trastuzumab remain incompletely understood, presenting a significant challenge to clinical practice.
Methods
In this study, we integrated genetic screening and bulk transcriptome and epigenomic profiling to define the mechanisms mediating adaptive resistance to HER2 inhibitors and identify potential effective therapeutic strategies for treating HER2-positive GCs.
Results
We revealed a potential association between adaptive resistance to trastuzumab in HER2-positive GC and the expression of YES-associated protein (YAP). Notably, our investigation revealed that long-term administration of trastuzumab triggers extensive chromatin remodeling and initiates YAP gene transcription in HER2-positive cells characterized by the initial inhibition and subsequent reactivation. Furthermore, treatment of HER2-positive GC cells and cell line-derived xenografts (CDX) models with YAP inhibitors in combination with trastuzumab was found to induce synergistic effects through the AKT/mTOR and ERK/mTOR pathways.
Conclusion
These findings underscore the pivotal role of reactivated YAP and mTOR signaling pathways in the development of adaptive resistance to trastuzumab and may serve as a promising joint target to overcome resistance to trastuzumab.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Medical Technology, Peking University Health Science Center, Beijing, 100191, China.
- Department of Laboratory Medicine, Peking University Third Hospital, Beijing, 100191, China.
- Core Unit of National Clinical Research Center for Laboratory Medicine, Peking University Third Hospital, Beijing, 100191, China.
- Translational Cancer Research Center, Peking University First Hospital, Beijing, 100034, China.
- Division of General Surgery, Peking University First Hospital, Peking University, No. 8 Xi Shiku Street, Beijing, 100034, China.
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department…
ORCID-Profile: Liyan Cui
Förderung
- Beijing Clinical Key Specialty Excellence Program, P. R. China
- Hospital-Enterprise Joint Funding Project
Zitieren
APA
Qiao, J., Feng, M., Zhou, W., Tan, Y., Yang, S., Liu, Q., Wang, Q., Feng, W., Pan, Y., & Cui, L. (2024). YAP inhibition overcomes adaptive resistance in HER2-positive gastric cancer treated with trastuzumab via the AKT/mTOR and ERK/mTOR axis. Gastric Cancer. https://doi.org/10.1007/s10120-024-01508-3
Vancouver
Qiao J, Feng M, Zhou W, Tan Y, Yang S, Liu Q, et al. YAP inhibition overcomes adaptive resistance in HER2-positive gastric cancer treated with trastuzumab via the AKT/mTOR and ERK/mTOR axis. Gastric Cancer. 2024. doi:10.1007/s10120-024-01508-3
BibTeX
@article{Qiao2024,
author = {Qiao, Jiao and Feng, Mei and Zhou, Wenyuan and Tan, Yuan and Yang, Shuo and Liu, Qi and Wang, Qingchen and Feng, Weimin and Pan, Yisheng and Cui, Liyan},
title = {YAP inhibition overcomes adaptive resistance in HER2-positive gastric cancer treated with trastuzumab via the AKT/mTOR and ERK/mTOR axis},
journal = {Gastric Cancer},
year = {2024},
doi = {10.1007/s10120-024-01508-3}
}
EUVIMED